Navigation Links
Discovery Labs to Host Conference Call to Discuss Third Quarter 2013 Results on Wednesday, November 13, 2013
Date:11/8/2013

WARRINGTON, Pa., Nov. 8, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO),  a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, will host a conference call at 10:00 a.m. ET on Wednesday, November 13, 2013 to discuss the third quarter financial results and other business updates.  A question-and-answer session will follow managements' remarks. The Company will report third quarter 2013 results on Tuesday, November 12, 2013 after the close of the U.S. financial markets. 

To access the conference call and participate in the question-and-answer session, the number for domestic callers is (877) 870-4263 and for international callers (412) 317-0790. The conference call replay number is (877) 344-7529 or (412) 317-0088. The passcode for the replay is 10036729.

The audio webcast of the conference call will be available on the Discovery Labs website at www.discoverylabs.com. It is recommended that participants log onto the audio webcast at least 15 minutes prior to the call. A replay of the audio webcast will be available after the call at the Company's website.

About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs' technology platforms include its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs' strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants.  Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy but are currently not treated.

For more information, please visit the Company's website at www.discoverylabs.com.


'/>"/>
SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research
3. Cellular Dynamics Announces Commercial Launch of iCellĀ® Neurons for Neuroscience Drug Discovery
4. Discovery of a dark state could mean a brighter future for solar energy
5. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
6. AnaptysBio Announces New Strategic Antibody Discovery
7. Discovery opens door to low-cost negative refraction, new products and industries
8. Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services
9. Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
10. AlphaBio Centrix, LLC Announces a New Discovery for Programming Energetic Patches
11. Mars, Incorporated Answers Question: How Does Feeding People and Pets Nurture Science and Discovery? At TEDMED 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:6/9/2016)... Paris Police Prefecture ... solution to ensure the safety of people and operations in ... major tournament Teleste, an international technology group specialised ... today that its video security solution will be utilised by ... public safety across the country. The system roll-out is scheduled ...
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):